Genocea Biosciences (GNCA) Stock: Cancer Vaccine Data Leads To Gains

Genocea Biosciences Inc (NASDAQ: GNCA) is grabbing the attention of investors this morning after announcing data from an early-stage clinical trial assessing a cancer vaccine. The data proved to be positive, leadint to excitement among investors and gains of more than 70% early in today’s trading session.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GNCA Stock Rockets On Positive Clinical Data

The news broke in the pre-market hours this morning via press release. The data came from the comapny’s ongoing Phase 1/2a trial of GEN-009, the lead product candidate at Genocea Biosciences.

Currently, the candidate is being developed as a neoantigen vaccine, also known as a cancer vaccine.

In the announcement, GNCA said that it presented the data in a poster presentation over the weekend at this year’s Annual Meeting of the American Society of Clinical Oncology, or ASCO. To view the full poster presentation, click here!

Clinical Trial Results

GEN-009 is proving to be a promising vaccine candidate. In fact, monotherapy with the treatment proved to lead to T cell responses in 91% of the vaccine neoantigens administered.

The data also showed that the vaccine has the unique ability to elicit ex vivo CD8+ T cell responses. This response was observed for 47% of vaccine neoantigens. Once you include the results seen after in vitro stimulation, this response frequency climbed to 53%.

Importantly, the data suggest that GEN-009 is safe and well tolerated among the target patient population. Moreover, GNCA said that there have been no dose-limiting toxicities to date.

Management Commentary

These data clearly differentiate ATLAS, our neoantigen discovery platform, from first-generation, machine-based approaches. As we continue to say, “targets matter,” and these data highlight the necessity of selecting the right neoantigens to drive immune responses in cancer patients. We believe that ATLAS holds the potential to benefit the clinical efficacy of both GEN-009 and GEN-011, our neoantigen-specific T cell therapy program, and to enable additional immunotherapy modalities. – Chip Clark, Genocea’s President & CEO.

Why This Is Important

Positive cancer vaccines are important in the treatment of the ailment. While tumors are generally treated with a wide range of therapies, cancer vaccines come into play after the treatment period has ended.

Essentially, when a patient goes into remission, cancer vaccines are used to destroy any residual cancer cells that could lead to the cancer reforming within the patient.

Of course, this is big business, and if GNCA continues down the line it is on, it will tap into this vast market, creating a strong opportunity to generate revenue ahead.

What We’ll Be Watching For Ahead

At CNA Finance, we’ll be following Genocea Biosciences incredibly closely. In particular, we’re interested in following the continued development of GEN-009 as the treatment seems to be yielding incredible results.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What Do You Think?

Where do you think GNCA is headed moving forward? Join the discussion in the comments below!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment